CONTENTS

Highlights of This Issue 5915

SPECIAL FEATURES

CCR Translations

5917  Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy  William E. Carson III

5920  Toward a Better Understanding of Race and Cancer  Otis W. Brawley

CCR Drug Updates

5923  Pazopanib in Renal Cell Carcinoma  James E. Ward and Walter M. Stadler

Molecular Pathways

5928  Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis  Xin Lu and Yibin Kang

5936  Targeting RET Receptor Tyrosine Kinase Activation in Cancer  John E. Phay and Manisha H. Shah

Review

5942  Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion  Lalita Subramanian, Sherry Youssef, Saswati Bhattacharya, Jason Kenealey, Arthur S. Polans and Paul R. van Ginkel

5950  Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease  Susan E. Bates

CCR Focus

5956  Translating Clinical Trials into Meaningful Outcomes  Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch and Walter Wolf

5963  Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed In the Right Direction?  Patricia M. LoRusso, Aparna B. Anderson, Scott A. Boerner and Steven D. Averbuch

5972  Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?  Tito Fojo and David R. Parkinson

5997  The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center  Justin F. Klamerus, Suanna S. Bruinooge, Xiaobu Ye, Mandi L. Klammerus, Dorothy Damron, Dina Lansey, John C. Lowery, Luis A. Diaz Jr., Jean C. Ford, Norma Kanarek and Charles M. Rudin

6004  Value and Cancer Care: Toward an Equitable Future  Lowell E. Schnipper, Neal J. Meropol and Dan W. Brock
**HUMAN CANCER BIOLOGY**

6009 IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer  
Zhi Liu, Dingxie Liu, Ermal Bojdani, Adel K. El-Naggar, Vasily Vasko and Mingzhao Xing

**CANCER THERAPY: PRECLINICAL**

6019 Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model  
Ping Yu, Jason C. Steel, Meili Zhang, John C. Morris and Thomas A. Waldmann

6029 Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma  
Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad and Harriet M. Kluger

6040 The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations  

**IMAGING, DIAGNOSIS, PROGNOSIS**

6083 Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification  
Bertil Damato, Justyna A. Dopierala, Sarah E. Coupland

6093 Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer  
Gustavo S.P. Meireles, Heiko Schöder, Gregory C. Ravizzini, Mithat Gonen, Josef J. Fox, John Fiummi, Michael J. Morris, Howard I. Scher and Steven M. Larson

**CANCER THERAPY: CLINICAL**

6122 CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma  
Mark E. Dudley, Colin A. Gross, Michelle M. Langhan, Marcos R. Garcia, Richard M. Sherry, James C. Yang, Giao Q. Phan, Uldai S. Kammula, Marybeth S. Hughes, Deborah E. Citrin, Nicholas P. Restifo, John R. Wunderlich, Peter A. Prieto, Jenny J. Hong, Russell C. Langan, Daniel A. Zlott, Kathleen E. Morton, Donald E. White, Carolyn M. Laurencot and Steven A. Rosenberg

6132 Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers  
Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil and Daniel Laheru
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
Denis C. Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies, Valérie André, Sunil Kadam, Michael Burgess, Christopher Slapak, Anna L. Olsen, Peter J. McHugh, Johann S. de Bono, Julian Matthews, Azeem Saleem and Patricia Price

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salier, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth and Nicholas Turner

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
Song Yao, William E. Barlow, Kathy S. Albain, Ji-Yeob Choi, Hua Zhao, Robert B. Livingston, Warren Davis, James M. Rae, J-Tien Yeh, Laura F. Hutchins, Peter M. Ravdin, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin Abeloff, Gabriel N. Hortobagyi, Daniel F. Hayes and Christine B. Ambrosone

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter
Cathy B. Moelans, Roel A. de Weert and Paul J. van Diest

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response
Leona Downey and Robert Livingston

Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?
Youji He, Laura J. Van’t Veer, Marta Lopez-Yurda, Cornelis J.H. van de Velde and Corrie A.M. Marijnen

Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter
Serge Koscielny and Stefan Michiels

Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response
Weida Tong and Xiaohui Fan

Acknowledgment to Reviewers
ABOUT THE COVER

Intracerebral xenograft initiated from the CD133⁺ glioblastoma stem-like cell line GBM1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.